Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 30 Show results per page	View Search Criteria \| Help With Results

Last Modified: 12/1/1993


1.		Phase III Study of Adjuvant Autolymphocyte Therapy for T1-3 N1-3 M0 or T4 N0-3 M0 Renal Cell Carcinoma (Summary Last Modified 12/93)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				over 18								CUCCC-90-C01 NCI-V91-0009

Last Modified: 9/1/1998


2.		Phase I/II Study of Activated Cytotoxic T Cells and Low-Dose Continuous-Infusion Interleukin-2 in Advanced Cancers (Summary Last Modified 09/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				Other				STLMC-BRM-9502 NCI-V95-0764

Last Modified: 5/23/2007


3.		Phase I/II Study of an Anti-T3 MoAb (OKT3) in Patients with Lymphoproliferative Disorders Bearing the T3 Antigen (Summary Last Modified 03/90)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				over 18				NCI				BRMP-8707B NCI-87-C-99B, NCI-T87-0175N, T87-0175

Last Modified: 7/30/2007


4.		Phase I/II Study of MOAB OKT3 with Low-Dose CTX in Patients with Advanced Malignancies (Summary Last Modified 09/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				Other				SVMC-ONC-121 NCI-V90-0206, NCT00002482

Last Modified: 12/23/2008


5.		Phase II Study of Autologous Tumor Cell Vaccine Therapy Followed by Adoptive Immunotherapy with Peripheral Blood Mononuclear Cells/IL-2 for Stage IV Melanoma (Summary Last Modified 07/94)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Other				KUMC-5699-93 NCI-V94-0426

Last Modified: 8/9/2006


6.		Phase II Study of Adjuvant Autologous Lymphocyte Therapy in Patients With High-Risk Renal Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				Over 16				Other				STLMC-BRM-9401 NCI-V94-0514, NCT00002589

Last Modified: 12/1/1999


7.		Phase II Study of Muromonab-CD3 (Orthoclone OKT3) plus Steroids and Cyclosporine in Acute Graft Versus Host Disease Prophylaxis Therapy Following Allogeneic Bone Marrow Transplantation (Summary Last Modified 12/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Supportive care, Treatment				Closed				5 to 65				NCI				RPCI-DS-96-67 NCI-G97-1247

Last Modified: 12/27/2008 First Published: 5/1/1998


8.		Phase II Study of Adoptive Cellular Therapy of Cancer Combining Direct HLA-B7/beta 2-Microglobulin Gene Transfer with Autologous Tumor Inoculation for the Generation of Tumor-Primed Anti-CD3 Activated Lymphocytes in Patients with Metastatic Renal Cell Carcinoma or Melanoma (Summary Last Modified 09/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Other				PPMC-IRB-94-53 OCC-ONC-9513-L, NCI-V98-1378

Last Modified: 12/27/2008 First Published: 9/1/1999


9.		Phase II Study of an Autologous Tumor Cell Vaccine and Adoptive Transfer of OKT3-Activated Autologous T Lymphocytes Following Surgery and Chemotherapy in Patients With Stage III or IV Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				WSU-C-1403-BR NCI-G99-1561, NCT00004018

Last Modified: 12/30/2008 First Published: 9/1/1999


10.		Phase II Study of an Autologous Tumor Cell Vaccine and Adoptive Transfer of OKT3-Activated Autologous T Lymphocytes Following Surgery and Chemotherapy in Patients With Stage II, III, or IV Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				WSU-C-1403-LU NCI-G99-1562, NCT00004019

Select All on One Page


					1 2 3 Next >

| | | | | | | |

A Service of the National Cancer Institute